Literature DB >> 14650919

Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system.

Nicolas Champtiaux1, Jean-Pierre Changeux.   

Abstract

The recent use of genetically engineered knockout (Ko) and knockin (Kin) animals for neurotransmitter receptor genes, in particular, nicotinic acetylcholine receptors (nAChRs) in the brain, has provided a powerful alternative to the classical pharmacological approach. These animal models are not only useful in order to reexamine and refine the results derived from pharmacological studies, but they do also provide a unique opportunity to determine the subunit composition of the nicotinic receptors which modulate various brain functions. Ultimately, this knowledge will be valuable in the process of designing new drugs that will mimic the effects of nicotine on several important pathologies or on smoking cessation therapies. In this review, we present recent data obtained from the studies of mutant animals that contributed to our understanding of the role and composition of nAChRs in the central nervous system (CNS). The advantages and pitfalls of Ko animal models will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14650919     DOI: 10.1016/s0079-6123(03)45016-4

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  24 in total

1.  Hippocampal α7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice.

Authors:  Yann S Mineur; Tenna N Mose; Sam Blakeman; Marina R Picciotto
Journal:  Br J Pharmacol       Date:  2017-04-08       Impact factor: 8.739

2.  Selective deletion of the alpha5 subunit differentially affects somatic-dendritic versus axonally targeted nicotinic ACh receptors in mouse.

Authors:  Harald Fischer; Avi Orr-Urtreger; Lorna W Role; Sigismund Huck
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

Review 3.  Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors.

Authors:  Bruce E McKay; Andon N Placzek; John A Dani
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

4.  Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.

Authors:  Maryka Quik; Carla Campos; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

5.  Brain activation by short-term nicotine exposure in anesthetized wild-type and beta2-nicotinic receptors knockout mice: a BOLD fMRI study.

Authors:  S V Suarez; A Amadon; E Giacomini; A Wiklund; J-P Changeux; D Le Bihan; S Granon
Journal:  Psychopharmacology (Berl)       Date:  2008-09-26       Impact factor: 4.530

6.  The Ferrier Lecture 1998. The molecular biology of consciousness investigated with genetically modified mice.

Authors:  Jean-Pierre Changeux
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-12-29       Impact factor: 6.237

7.  α4β2 nicotinic acetylcholine receptors in the early postnatal mouse superior cervical ganglion.

Authors:  Petra Scholze; Anna Ciuraszkiewicz; Florian Groessl; Avi Orr-Urtreger; J Michael McIntosh; Sigismund Huck
Journal:  Dev Neurobiol       Date:  2011-05       Impact factor: 3.964

8.  An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants.

Authors:  Christopher G Baddick; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2011-05-10       Impact factor: 5.858

Review 9.  The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer.

Authors:  Ma Reina D Improgo; Michael D Scofield; Andrew R Tapper; Paul D Gardner
Journal:  Prog Neurobiol       Date:  2010-06-04       Impact factor: 11.685

10.  Trace eyeblink conditioning is impaired in α7 but not in β2 nicotinic acetylcholine receptor knockout mice.

Authors:  Kevin L Brown; David M Comalli; Mariella De Biasi; Diana S Woodruff-Pak
Journal:  Front Behav Neurosci       Date:  2010-10-08       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.